How can the human microbiome affect a cancer patient’s response to standard treatment?

In the context of translational medicine, research into the human microbiome has revealed that the composition of intestinal flora can significantly influence how a cancer patient responds to standard treatments.1

Specifically, alterations in the gut microbiota can modulate the patient's immune response, which in turn affects the efficacy of cancer therapies. This interaction highlights that a patient's response to treatment is a multifactorial phenomenon, shaped by the complex interplay between their unique genetic background, environmental factors, and the commensal microorganisms inhabiting their body.1

By integrating these insights, translational medicine aims to advance personalized medicine, where understanding an individual's specific microbial and genetic profile helps clinicians predict treatment responsiveness and develop more effective, patient-specific therapeutic strategies.1